The lung cancer incidence increasingly rises and draws much attention under the environment that the haze becomes increasingly serious and the air for the survival of human kinds becomes worse and worse. In China, lung cancer is the cancer with the highest incidence among all the cancers, accounting for more than 10% of all cancers. It is already the middle and advanced stage when patients with lung cancer are diagnosed because its early symptoms are not apparent. As a result, the basis for many lung cancer patients to "sustain their lives" is the necessary effective targeting drug treatment. I will review the world’s lung cancer targeting drugs in the followings.
Table 1 World’s lung cancer targeting drugs
|
Name of the Drug |
Targets |
Company |
|
Gefitinib |
EGFR (HER1/ERBB1) |
AZ |
|
Eriotinib |
EGFR (HER1/ERBB1) |
Roche, Genentech |
|
Necitumumab |
EGFR (HER1/ERBB1) |
Lilly |
|
Osimertinib |
EGFR (HER1/ERBB1) |
AZ |
|
Afatinib |
EGFR (HER1, 2/ERBB1) |
Boehringer-Ingelheim |
|
Geritinib |
ALK |
Norvatis |
|
Alectinib |
ALK |
Roche |
|
Crizotinib |
ALK, MET, ROS1 |
Pfizer |
|
Nivolumab |
PD-1 |
BMS |
|
Pembrolizumab |
PD-1 |
Merck & Co |
|
Ramucirumab |
VEGFR2 |
Lilly |
|
Bevacizumab |
VEGF |
Roche |
Seen from Table 1, Roche has Eriotinib, Alectinib and Bevacizumab among the multiple lung cancer targeting drug manufacturers, and is the pharmaceutical enterprise with the most lung cancer targeting drugs, with many targets involved including EGFR, ALK and VEGF, wherein, as a lung cancer drug newly approved to be marketed in 2016, Alectinib is used to treat metastatic/advanced ALK-positive non-small cell lung cancer (NSCLC) and mainly for patients whose disease has progressed on or who are intolerant of Crizotinib, a lung cancer drug under Pfizer. As a kinase inhibitor targeting ALK, Alectinib can inhibit ALK phosphorylation and ALK-mediated downstream targets STAT3 and AKT, and furthermore, the major metabolite M4 of Alectinib has been proved to have good activity ...
(All Rights Reserved)